A fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia: Identification and analysis of a candidate tumor suppressor gene

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4089-4098

  Sinclair, Paul B ^a   Sorour, Amani ^a   Martineau, Mary ^a,b   Harrison, Christine J ^a,b   Mitchell, Wayne A ^a   O'Neill, Elena ^a   Foroni, Letizia ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; DNA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTAMATE RECEPTOR; IONOTROPIC RECEPTOR; KAINIC ACID; RNA;

ACUTE LYMPHOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ARTICLE; CHROMOSOME 6; CHROMOSOME DELETION; CHROMOSOME DELETION 6; CHROMOSOME MAP; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE IDENTIFICATION; GRIK2 GENE; HETEROZYGOSITY; HUMAN; HUMAN CELL; KIDNEY TUMOR; LUNG TUMOR; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; THYMUS; TRACHEA TUMOR; TUMOR SUPPRESSOR GENE;

ADOLESCENT; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 6; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENES, TUMOR SUPPRESSOR; HEMATOPOIETIC SYSTEM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JURKAT CELLS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, T-CELL; LOSS OF HETEROZYGOSITY; MALE; MOLECULAR SEQUENCE DATA; PHYSICAL CHROMOSOME MAPPING; RECEPTORS, KAINIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 3042526114     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1871     Document Type: Article

References (67)

1. Lu YJ, Xiao S, Yan YS, Fu SB, Liu QZ, Li P. Direct chromosome analysis of 50 primary breast carcinomas. Cancer Genet Cytogenet 1993;69:91-9.
2. Visakorpi T, Kallioniemi AH, Syvanen AC, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995; 55:342-7.
3. Thompson FH, Emerson J, Alberts D, et al. Clonal chromosome abnormalities in 54 cases of ovarian carcinoma. Cancer Genet Cytogenet 1994;73:33-45.
4. Ozisik YY, Meloni AM, Altungoz O, et al. Cytogenetic findings in 21 malignant melanomas. Cancer Genet Cytogenet 1994;77:69-73.
5. Mertens F, Johansson B, Hoglund M, Mitelman F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 1997; 57:2765-80.
6. Mitelman F. Catalog of chromosome aberrations in cancer. New York: Wiley-Liss; 1994.
7. Miyakawa A, Ichimura K, Schmidt EE, Varmeh-Ziaie S, Collins VP. Multiple deleted regions on the long arm of chromosome 6 in astrocytic tumours. Br J Cancer 2000;82:543-9.
8. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-9.
9. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 1996;56:4150-3.
10. Orphanos V, McGown G, Hey Y, et al. Allelic imbalance of chromosome 6q in ovarian tumours. Br J Cancer 1995;71:666-9.
11. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J. Natl Cancer Inst (Bethesda) 1998;90:697-703.
12. Sheng ZM, Marchetti A, Buttitta F, et al. Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. Br J Cancer 1996; 73:144-7.
13. Offit K, Chaganti RS. Chromosomal aberrations in non-Hodgkin's lymphoma. Biologic and clinical correlations. Hematol Oncol Clin N Am 1991;5:853-69.
14. Raimondi SC. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993;81:2237-51.
15. Hayashi Y, Raimondi SC, Look AT, et al. Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. Blood 1990;76:1626-30.
16. Kamada N, Sakurai M, Miyamoto K, et al. Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report. Cancer Res 1992;52: 1481-93.
17. Glassman AB, Harper-Allen EA, Hayes KJ, Hopwood VL, Gutterman EE, Zagryn SP. Chromosome 6 abnormalities associated with prolymphocytic acceleration in chronic lymphocytic leukemia. Ann Clin Lab Sci 1998;28:24-9.
18. Wong KF, Chan JK, Kwong YL. Identification of de1(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia. Br J Haematol 1997;98:922-6.
19. Offit K, Parsa NZ, Gaidano G, et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 1993;82:2157-62.
20. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood 1996;87:3135-42.
21. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol 1997;96:601-10.
22. Walters R, Kantarjian HM, Keating MJ, et al. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am J Med 1990;89:579-87.
23. Mancini M, Vegna ML, Castoldi GL, et al. Partial deletions of the long arm of chromosome 6: biologic and clinical implications in adult lymphocytic leukemia. Leukemia (Baltimore) 2002;16:2055-61.
24. Heerema NA, Sather HN, Sensel MG, et al. Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma 2000;36:467-78.
25. Menasce LP, Orphanos V, Santibanez-Koref M, Boyle JM, Harrison CJ. Common region of deletion on the long arm of chromosome 6 in non-Hodgkin's lymphoma and acute lymphoblastic leukaemia. Genes Chromosomes Cancer 1994;10:286-8.
26. Sherratt T, Morelli C, Boyle JM, Harrison CJ. Analysis of chromosome 6 deletions in lymphoid malignancies provides evidence for a region of minimal deletion within a 2-megabase segment of 6q21. Chromosome Res 1997;5:118-24.
27. Jackson A, Carrara P, Duke V, et al. Deletion of 6q16-q21 in human lymphoid malignancies: a mapping and deletion analysis. Cancer Res 2000;60:2775-9.
28. Zhang Y, Matthiesen P, Harder S, et al. A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosomes Cancer 2000;27:52-8.
29. Gerard B, Cave H, Guidal C, Dastugue N, Vilmer E, Grandchamp B. Delineation of a 6-cM commonly deleted region in childhood acute lymphoblastic leukemia on the 6q chromosomal arm. Leukemia (Baltimore) 1997;11:228-32.
30. Takeuchi S, Koike M, Seriu T, et al. Frequent loss of heterozygosity on the long arm of chromosome 6: identification of two distinct regions of deletion in childhood acute lymphoblastic leukemia. Cancer Res 1998;58:2618-23.
31. Merup M, Moreno TC, Heyman M, et al. 6q deletions in acute lymphoblastic leukemia and non-Hodgkin's lymphomas. Blood 1998;91:3397-400.
32. Hatta Y, Yamada Y, Tomonaga M, Miyoshi I, Said JW, Koeffler HP. Detailed deletion mapping of the long arm of chromosome 6 in adult T-cell leukemia. Blood 1999;93:613-6.
33. Mitelman F. An international system for human cytogenetic nomenclature. Basel, Switzerland: Karger; 1995.
34. Harrison CJ, Martineau M, Secker-Walker LM. The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management. Br J Haematol 2001;113:3-10.
35. Mungall AJ, Palmer SA, Sims SK, et al. The DNA sequence and analysis of human chromosome 6. Nature (Lond.) 2003;425:805-11.
36. Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997;90:1395-402.
37. Mortuza FY, Moreira IM, Papaioannou M, et al. Immunoglobulin heavy-chain gene rearrangement in adult acute lymphoblastic leukemia reveals preferential usage of J(H)-proximal variable gene segments. Blood 2001;97:2716-26.
38. Foroni L, Sorour AF, Sinclair PB, Duke VD. Loss of heterozygosity (LOH) and microsatellite instability (MSI) of chromosome 6q16-21 identifies a prognostically poor group of childhood and adult T-cell precursor acute lymphoblastic leukaemia (ALL) patients. Blood. 2003;102:606.
39. Barbon A, Vallini I, Barlati S. Genomic organization of the human GRIK2 gene and evidence for multiple splicing variants. Gene (Amst.) 2001;274:187-97.
40. Devaraj PE, Foroni L, Janossy G, Hoffbrand AV, Secker-Walker LM. Expression of the E2A-PBX1 fusion transcripts in t(1;19)(q23; p13) and der(19)t(1;19) at diagnosis and in remission of acute lymphoblastic leukemia with different B lineage immunophenotypes. Leukemia (Baltimore) 1995;9:821-5.
41. Michaud JL, Rosenquist T, May NR, Fan CM. Development of neuroendocrine lineages requires the bHLH-PAS transcription factor SIM1. Genes Dev 1998;12: 3264-75.
42. Hill J, Duckworth M, Murdock P, et al. Molecular cloning and functional characterization of MCH2, a novel human MCH receptor. J Biol Chem 2001;276:20125-9.
43. Savinainen A, Garcia EP, Dorow D, Marshall J, Liu YF. Kainate receptor activation induces mixed lineage kinase-mediated cellular signaling cascades via post-synaptic density protein 95. J Biol Chem 2001;276:11382-6.
44. Akoulitchev S, Chuikov S, Reinberg D. TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature (Lond.) 2000;407:102-6.
45. Liu ZJ, Tanaka Y, Mine S, et al. Functional cooperation of cyclin C and c-Myc in mediating homotypic cell adhesion via very late antigen-4 activation and vascular cell adhesion molecule-1 induction. Blood 1998;92:4700-11.
46. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000;130:1007S-15S.
47. Ikonomidou C, Bosch F, Miksa M, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science (Wash. DC) 1999;283:70-4.
48. Behar TN, Scott CA, Greene CL, et al. Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. J Neurosci 1999;19:4449-61.
49. Komuro H, Rakic P. Modulation of neuronal migration by NMDA receptors. Science (Wash. DC) 1993;260:95-7.
50. Cavalheiro EA, Olney JW. Glutamate antagonists: deadly liaisons with cancer. Proc Natl Acad Sci USA 2001;98:5947-8.
51. Li H, Lahti JM, Valentine M, et al. Molecular cloning and chromosomal localization of the human cyclin C (CCNC) and cyclin E (CCNE) genes: deletion of the CCNC gene in human tumors. Genomics 1996;32:253-9.
52. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002;99:8242-7.
53. Mulle C, Sailer A, Perez-Otano I, et al. Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice. Nature (Lond.) 1998;392:601-5.
54. + and T-cell function. Trends Immunol 2001;22:2-5.
55. Kostanyan IA, Merkulova MI, Navolotskaya EV, Nurieva RI. Study of interaction between L-glutamate and human blood lymphocytes. Immunol Lett 1997;58:177-80.
56. Eck HP, Frey H, Droge W. Elevated plasma glutamate concentrations in HIV-1-infected patients may contribute to loss of macrophage and lymphocyte functions. Int Immunol 1989;1:367-72.
57. Droge W, Eck HP, Betzler M, Schlag P, Drings P, Ebert W. Plasma glutamate concentration and lymphocyte activity. J Cancer Res Clin Oncol 1988;114:124-8.
58. Eck HP, Betzler M, Schlag P, Droge W. Partial recovery of lymphocyte activity in patients with colorectal carcinoma after curative surgical treatment and return of plasma glutamate concentrations to normal levels. J Cancer Res Clin Oncol 1990; 116:648-50.
59. Eck HP, Drings P, Droge W. Plasma glutamate levels, lymphocyte reactivity and death rate in patients with bronchial carcinoma. J Cancer Res Clin Oncol 1989;115: 571-4.
60. Ganor Y, Besser M, Ben-Zakay N, Unger T, Levite M. Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J Immunol 2003;170:4362-72.
61. Pollock PM, Cohen-Solal K, Sood R, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003;34:108-12.
62. Arai Y, Takashima S, Becker LE. Down-regulation of glutamate receptor subunit 2(3) in subependymal giant-cell tumor. Pediatr Neurol 2000;23:37-41.
63. Markert JM, Fuller CM, Gillespie GY, et al. Differential gene expression profiling in human brain tumors. Physiol Genomics 2001;5:21-33.
64. Rzeski W, Turski L, Ikonomidou C. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 2001;98:6372-7.
65. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med 2001;7:1010-5.
66. Klegeris A, Walker DG, McGeer PL. Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. J Neuroimmunol 1997;78:152-61.
67. Gill SS, Pulido OM, Mueller RW, McGuire PF. Molecular and immunochemical characterization of the ionotropic glutamate receptors in the rat heart. Brain Res Bull 1998;46:429-34.